Novartis is to buy US biotech IFM Tre in a deal worth up to $1.575 billion, adding a potential drug for the fatty liver disease known as NASH to its pipeline. IFM Tre is a subsidiary of cancer biotech ...
IFM Investors moved on Atlas Arteria with a $6.9 billion buyout bid after the ASX-listed toll road operator indicated it would not listen to its largest shareholder and consider pursuing an expensive ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results